ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

J&J Provides Added Doxil Supply for Clinical Studies

By Peter Loftus Johnson & Johnson (JNJ) will provide additional supply of its cancer drug Doxil for use in clinical trials, including one testing whether the combination of an experimental Endocyte Inc. (ECYT) drug with Doxil improves treatment of ovarian cancer. Doxil has been in short supply since J&J's contract manufacturer experienced factory problems last year. Apart from affecting patients who were prescribed Doxil, the shortage also held up clinical trials of experimental drugs that were being tested with or against Doxil. J&J said Thursday it would provide supplies of Doxil to two clinical trials. One is a late-stage study testing whether Endocyte's EC145 and Doxil improves overall survival of women with ovarian cancer, versus Doxil alone. Endocyte said in a separate statement the additional Doxil would supplement an existing supply that was already in place to support the trial, and would allow the company to continue to enroll patients without interruption. Endocyte in April agreed to license EC145 to Merck & Co. (MRK), which gained global rights to develop and commercialize the drug in exchange for a $120 million up-front payment and up to $880 million in additional payments if certain milestones are met. Endocyte retains the right to co-promote the drug with Merck in the U.S. In addition, J&J will supply Doxil to be used in a clinical trial of VentiRx Pharmaceuticals' experimental cancer drug VTX-2337. J&J said its Doxil supplier, Boehringer Ingelheim's Ben Venue Laboratories unit, is making progress toward resuming production of Doxil near the end of this year. Ben Venue suspended production late last year as it tried to fix manufacturing problems identified by drug regulators. J&J has been allocating remaining supplies of Doxil through a rationing program. Earlier this year, the Food and Drug Administration approved the temporary importation of a replacement drug for Doxil, known as Lipodox. J&J said it will continue to pursue a shorter-term option to begin restoring Doxil supplies before the end of the year. Write to Peter Loftus at peter.loftus@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
05/22/201521:10:00MSD reçoit de la part du CHMP un avis favorable concernant le...
05/22/201507:12:00Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab...
05/22/201507:12:00MSD Receives Positive CHMP Opinion for Pembrolizumab for the...
05/20/201512:15:10What Is the S&P 500 Index?
05/18/201521:09:03The 30 Dow Jones Stocks
05/18/201512:18:57Endo to Buy Generics Maker Par Pharma for $8 Billion -- 4th Update
05/18/201511:05:26Endo to Buy Generics Maker Par Pharma for $8 Billion -- 3rd Update
05/18/201509:20:13Endo to Buy Par Pharma
05/18/201508:53:55Endo to Buy Generics Maker Par Pharma for $8 Billion -- 2nd Update
05/18/201508:00:00Merck to Present at the UBS Global Healthcare Conference
05/18/201507:44:29Endo to Buy Generics Maker Par Pharma for About $8 Billion...
05/17/201520:04:30M&A Fuels Fundraising
05/17/201509:05:022 Stocks With Jaw-Dropping Growth Potential
05/17/201508:04:02Big Pharma Stocks: Where to Invest Your Money Now
05/14/201509:04:02How a Strong Dollar Affects Pharmaceutical Stocks
05/13/201517:00:002015 ASCO Annual Meeting: New Data in 10 Different Cancers from...
05/12/201510:26:025 Largest Markets for Pharmaceuticals
05/11/201517:50:13Statement of Changes in Beneficial Ownership (4)
05/11/201513:34:59Statement of Changes in Beneficial Ownership (4)
05/07/201516:58:56Quarterly Report (10-q)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad